Merck SWOT Analysis: Strengths, Weaknesses, Opportunities and Threats
Merck's edge rests on the scale of its Keytruda clinical program, with more than 40 approved indications, plus a large biologics manufacturing network and a vaccine franchise built over decades. Each new Keytruda approval reuses the same oncology sales relationships and safety data, which lowers the cost of every additional indication. The September 2025 approval of subcutaneous Keytruda Qlex, which sold $463 million in Q2 2026, gives Merck a newer formulation to move patients onto before IV biosimilars arrive. Animal Health adds a steadier, less patent-driven profit stream.
Top strength: Keytruda Franchise Dominance Across Oncology Spectrum. Primary risk: IRA Pricing Negotiation Expansion to Keytruda.
- What are Merck's strengths?
- The main strengths in this analysis are: Keytruda Franchise Dominance Across Oncology Spectrum; Sales and Profit Scale.
- What are Merck's weaknesses?
- The main weaknesses in this analysis are: Extreme Revenue Concentration in a Single Product Facing Patent Expiry; Gardasil's Collapse in China.
SWOT Analysis: Merck & Co., Inc.
Strengths
- Keytruda's approval across more than 40 cancer indications and its more than 1,600 active clinical trials create a clinical evidence base and physician relationship network that represents the most strong competitive position in the pharmaceutical industry today. The drug's dominance in first-line non-small cell lung cancer, the single most commercially valuable oncology indication globally, with U.S. Market share exceeding 50 percent, generates a revenue anchor that funds Merck's aggressive pipeline investment and sustains the research and commercial infrastructure required to develop its successor franchise. Aftermarket gross margins on Keytruda and comparable biologics consistently exceed 75 percent, making the franchise one of the most cash-generative assets in corporate America and supporting approximately $16.4 billion in annual R&D investment.
- Merck reported $65.0 billion in 2025 sales and $18.3 billion in net income attributable to Merck, and Animal Health grew 8% to $1.8 billion in Q2 2026. Source: sec.gov
Weaknesses
- Keytruda's US$31.7 billion in fiscal year 2025 sales represents roughly 49 percent of total company sales, a level of product concentration that creates a structurally fragile financial profile when that product faces patent-driven competitive disruption in 2028. No pharmaceutical company has ever replaced blockbuster revenue of this magnitude from internal pipeline alone, and Merck's acquisition and partnership spending of approximately $50 billion since 2021 reflects management's clear-eyed recognition that the internal research pipeline was not sufficient to fill the gap. The concentration also creates vulnerability to U.S. Drug pricing policy, as any expansion of IRA negotiation authority to pembrolizumab would have immediate and material financial consequences with limited commercial mitigation options.
- Gardasil sales fell 39% to $5.2 billion in 2025 after demand in China collapsed, showing how one government's procurement decisions can move billions in revenue.
Opportunities
- Subcutaneous pembrolizumab (Keytruda Qlex, FDA-approved on September 19, 2025), a formulation allowing injection in approximately five minutes versus 30-minute intravenous administration, could substantially reduce the commercial attractiveness of biosimilar IV pembrolizumab for both patients and prescribers by offering a superior convenience profile under separate patent protection extending into the 2030s. Simultaneously, Keytruda's ongoing evaluation as adjuvant therapy in earlier-stage cancers following surgical resection is expanding the eligible patient population well beyond the metastatic and advanced-stage patients who represent its current commercial base, with adjuvant approvals in melanoma, renal cell carcinoma, and non-small cell lung cancer already contributing incremental revenue and additional adjuvant programs in earlier-stage disease actively enrolling.
- Between October 2025 and mid-2026 Merck closed the Verona Pharma (about $10 billion), Cidara Therapeutics (about $9.2 billion) and Terns Pharmaceuticals (about $6.7 billion) deals, adding the marketed COPD drug Ohtuvayre, the long-acting influenza preventive CD388 and the CML candidate MK-4208. Together with the 2026 FDA approval of oral PCSK9 inhibitor Lipfendra, these give Merck more non-oncology growth options ahead of the Keytruda patent cliff. Source: merck.com
Threats
- The Inflation Reduction Act's Medicare drug price negotiation framework represents the most significant structural threat to Merck's near-term financial profile. While sitagliptin was selected in the first round of negotiation with a price reduction of approximately 79 percent, Keytruda's scale of Medicare expenditure, it is among the single highest-cost physician-administered Medicare Part B drugs, makes it a logical candidate for future negotiation rounds as the program expands. A negotiated Keytruda price covering even the Medicare population, which represents a substantial fraction of cancer patients in the United States, would reduce Merck's domestic revenue from its most important product by several billion dollars annually. Merck's legal challenges to the IRA negotiation provisions have not yet succeeded in the courts, and the political environment for their reversal through legislative action appears limited.
- Keytruda's key U.S. patent protection begins to expire in 2028, opening the door to biosimilar pembrolizumab.
Merck SWOT Analysis FAQ
What are the primary competitive strengths of Merck & Co.?
Merck's strengths include the world's most dominant oncology asset (Keytruda), market leadership in HPV cancer prevention vaccines (Gardasil 9), exceptional biopharma R&D capabilities, top global clinical trial execution, strong balance sheet liquidity, and an expanding antibody-drug conjugate (ADC) oncology pipeline.
What are the primary external threats to Merck's business model?
Major threats include US Medicare drug price negotiations under the Inflation Reduction Act (IRA), biosimilar competition post-2028, clinical trial failures in late-stage Phase 3 pipelines, pricing pressure in international vaccine procurement, and regulatory delays at the FDA and EMA.
How does the 'Keytruda Patent Cliff' in 2028 impact Merck's long-term strategy?
The expiration of foundational composition-of-matter patents for Keytruda around 2028 to 2030 will allow lower-cost biosimilar versions to enter global markets. Merck is actively buffering this cliff through subcutaneous formulations, new combination regimens, Winrevair, and strategic M&A.
How does the Inflation Reduction Act (IRA) affect Merck's US drug pricing?
Under the IRA, the US federal government selected Januvia for initial Medicare price negotiations, with Keytruda eligible for future negotiation cycles. Merck has challenged the law in federal court while adjusting its commercial portfolio toward earlier-line indications and rare-disease therapies.
How does Merck manage global access and affordable pricing in developing countries?
Through voluntary licensing agreements (such as with the Medicines Patent Pool for molnupiravir), tiered international vaccine pricing, and the Mectizan Donation Program, Merck expands global health access while protecting intellectual property in developed commercial markets.
How does the US Inflation Reduction Act (IRA) impact Merck?
The Inflation Reduction Act authorizes Medicare to directly negotiate prices for top-selling single-source drugs. Blockbuster therapies like Keytruda and Januvia face government price discount mandates once eligible. Merck filed legal challenges against the law, arguing it unconstitutionally depresses R&D returns, while aggressively seeking accelerated commercialization of pipeline assets immune to early IRA negotiations.